» Articles » PMID: 36619998

The Clinical Characteristics and Risk Factors for Severe COVID-19 in Patients with COVID-19 and Tuberculosis Coinfection

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2023 Jan 9
PMID 36619998
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Under the wave of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variant Omicron epidemic, the number of infectious cases has increased dramatically in Jilin Province, China since March 2022.The clinical features and severity of SARS-CoV-2 Omicron variant infection in tuberculosis (TB) patients are not yet clear.

Methods: Data were obtained from 153 patients with the Omicron variant and TB coinfection and 153 non-TB COVID-19 patients who had been hospitalized at Changchun Infectious Disease Hospital from March to June 2022.

Results: Among these coinfection patients, 17 patients showed COVID-19-related pneumonia on chest imaging and 11 were diagnosed with severe COVID-19. The median duration of SARS-CoV-2 clearance was 13 days. The negative conversion time was associated with age, COVID-19-related pneumonia and antibody IgG. A higher white blood cell count, a lower lymphocyte percentage, a higher CRP level, and a higher D-dimer level were found in the severe group. Age and increased PCT were individual risk factors for the severity of COVID-19. Compared with the non-TB patients, the coinfection patients had higher severity of COVID-19 and the elder coinfection patients had a longer negative conversion time.

Conclusion: This study found an association between age, pneumonia, antibody IgG and RNA negative conversion time in COVID-19 and TB coinfection patients, and age and increased PCT were risk factors for the severity of COVID-19.

Citing Articles

Associations between genetic mutations in different SARS-CoV-2 strains and negative conversion time of viral RNA among imported cases in Hangzhou: A cross-sectional study.

Wang Y, Yu H, Zhang T, Sun Z, Yao W, Zhang W Virus Res. 2024; 345:199400.

PMID: 38763300 PMC: 11137596. DOI: 10.1016/j.virusres.2024.199400.


Systematic review and meta-analysis of Tuberculosis and COVID-19 Co-infection: Prevalence, fatality, and treatment considerations.

Wang Q, Cao Y, Liu X, Fu Y, Zhang J, Zhang Y PLoS Negl Trop Dis. 2024; 18(5):e0012136.

PMID: 38739637 PMC: 11090343. DOI: 10.1371/journal.pntd.0012136.


The Important Role of Preoperative D-Dimer in Constrictive Pericarditis.

Fang L, Zhong F, Yu W, Zhu P, Yu G Ther Clin Risk Manag. 2024; 20:239-247.

PMID: 38736988 PMC: 11087889. DOI: 10.2147/TCRM.S462075.


Suppressive myeloid cells in SARS-CoV-2 and co-infection.

Shaw J, Malherbe S, Walzl G, Plessis N Front Immunol. 2023; 14:1222911.

PMID: 37545508 PMC: 10399583. DOI: 10.3389/fimmu.2023.1222911.

References
1.
Pai M, Kasaeva T, Swaminathan S . Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022; 386(16):1490-1493. DOI: 10.1056/NEJMp2118145. View

2.
Li H, Gao M, You H, Zhang P, Pan Y, Li N . Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With.... Clin Infect Dis. 2022; 76(3):e148-e154. PMC: 9384507. DOI: 10.1093/cid/ciac600. View

3.
Long Q, Guo L, Jiang W, Huan S, Tang S . Ending tuberculosis in China: health system challenges. Lancet Public Health. 2021; 6(12):e948-e953. DOI: 10.1016/S2468-2667(21)00203-6. View

4.
. Tuberculosis and COVID-19 co-infection: description of the global cohort. Eur Respir J. 2021; 59(3). PMC: 8588566. DOI: 10.1183/13993003.02538-2021. View

5.
Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M . Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. Int J Infect Dis. 2021; 116:38-42. PMC: 8713416. DOI: 10.1016/j.ijid.2021.12.357. View